Reports
Reports
Sale
North America accounted for a significant share of the global market and is expected to grow rapidly during the forecast period. The leading position of the region can be attributed to factors like excellent healthcare infrastructure, effective government policies, large base of multinational corporations, and high public awareness about diagnosis and medical assistance.
On the other hand, the Asia Pacific region is also expected to witness significant growth in the coming years due to the higher presence of the emerging regions and their potential of growth. The regional market is likely to witness further growth due to the competitive strategies that are adopted by players to conduct research and development activities in this sector. Also, the growth of various pharmaceutical companies in this region is another factor that is fuelling the growth of exosomes drug market.
Exosomes Drug Market Regional Analysis
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Exosomes Drug Overview
4.1 Drug Overview
4.1.1 Pharmacodynamics
4.1.2 Pharmacokinetics
4.1.3 Adverse Events
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Exosomes Drug Market
6.1 Global Exosomes Drug Market Overview
6.2 Global Exosomes Drug Market Analysis
6.2.1 Market Overview
6.2.1.1 Global Exosomes Drug Market Historical Value (2017-2023)
6.2.1.2 Global Exosomes Drug Market Forecast Value (2024-2032)
6.3 Global Exosomes Drug Market by Biomolecule Type
6.3.1 Market Overview
6.3.1.1 Non-Coding RNAs
6.3.1.2 mRNA (exoRNA)
6.3.1.3 Proteins/Peptides
6.3.1.4 DNA Fragments
6.3.1.5 Lipids
6.4 Global Exosomes Drug Market by Product Type
6.4.1 Market Overview
6.4.1.1 Kits
6.4.1.2 Reagents
6.4.1.3 Instruments
6.5 Global Exosomes Drug Market by Application
6.5.1 Market Overview
6.5.1.1 Biomarkers
6.5.1.2 Drug Delivery System
6.5.1.3 Vaccine Development
6.5.1.4 Therapeutic Agents
6.5.1.5 Others
6.6 Global Exosomes Drug Market by Disease Type
6.6.1 Market Overview
6.6.1.1 Cancer Disease
6.6.1.2 Neurodegenerative Diseases
6.6.1.3 Cardiovascular Diseases
6.6.1.4 Infectious Diseases
6.6.1.5 Tissue Regeneration
6.6.1.6 Others
6.7 Global Exosomes Drug Market by Region
6.7.1 Market Overview
6.7.1.1 North America
6.7.1.2 Europe
6.7.1.3 Asia Pacific
6.7.1.4 Latin America
6.7.1.5 Middle East and Africa
7 North America Exosomes Drug Treatment Market
7.1 Market Share by Country
7.2 United States of America
7.2.1 Historical Trend (2017-2023)
7.2.2 Forecast Trend (2024-2032)
7.3 Canada
7.3.1 Historical Trend (2017-2023)
7.3.2 Forecast Trend (2024-2032)
8 Europe Exosomes Drug Treatment Market
8.1 Market Share by Country
8.2 United Kingdom
8.2.1 Historical Trend (2017-2023)
8.2.2 Forecast Trend (2024-2032)
8.3 Germany
8.3.1 Historical Trend (2017-2023)
8.3.2 Forecast Trend (2024-2032)
8.4 France
8.4.1 Historical Trend (2017-2023)
8.4.2 Forecast Trend (2024-2032)
8.5 Italy
8.5.1 Historical Trend (2017-2023)
8.5.2 Forecast Trend (2024-2032)
8.6 Others
9 Asia Pacific Exosomes Drug Treatment Market
9.1 Market Share by Country
9.2 China
9.2.1 Historical Trend (2017-2023)
9.2.2 Forecast Trend (2024-2032)
9.3 Japan
9.3.1 Historical Trend (2017-2023)
9.3.2 Forecast Trend (2024-2032)
9.4 India
9.4.1 Historical Trend (2017-2023)
9.4.2 Forecast Trend (2024-2032)
9.5 ASEAN
9.5.1 Historical Trend (2017-2023)
9.5.2 Forecast Trend (2024-2032)
9.6 Australia
9.6.1 Historical Trend (2017-2023)
9.6.2 Forecast Trend (2024-2032)
9.7 Others
10 Latin America Exosomes Drug Treatment Market
10.1 Market Share by Country
10.2 Brazil
10.2.1 Historical Trend (2017-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 Argentina
10.3.1 Historical Trend (2017-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Mexico
10.4.1 Historical Trend (2017-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Middle East and Africa Exosomes Drug Treatment Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.2.1 Historical Trend (2017-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 United Arab Emirates
11.3.1 Historical Trend (2017-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 Nigeria
11.4.1 Historical Trend (2017-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 South Africa
11.5.1 Historical Trend (2017-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Current Scenario Evaluation and Regulatory Framework
12.1 Emerging Therapies and Clinical Trials Synopsis
12.2 Patent Landscape
12.2.1 Patent Overview
12.2.1.1 Patent Status and Expiry
12.2.1.2 Timelines from Drug Development to Commercial Launch
12.2.1.3 New Drug Application
12.2.1.3.1 Documentation and Approval Process
12.3 Cost of Treatment
12.4 Investment Scenarios
12.5 Regulatory Framework
12.5.1 Regulatory Overview
12.5.1.1 US FDA
12.5.1.2 EU EMA
12.5.1.3 INDIA CDSCO
12.5.1.4 JAPAN PMDA
12.5.1.5 Others
13 Challenges and Unmet Need
13.1 Treatment Pathway Challenges
13.2 Compliance and Drop-Out Rate
13.3 Awareness and Prevention Gaps
14 Global Exosomes Drug Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Drug Adoption Parameters
14.4 Porter’s Five Forces Model
14.5 Key Demand Indicators
14.6 Key Price Indicators
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Danaher Corporation (Beckman Coulter Inc.)
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Hologic Inc.
15.2.1 Company Overview
15.2.2 Product portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Lonza Group AG
15.3.1 Company Overview
15.3.2 Product portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Fujifilm Holdings Corporation
15.4.1 Company Overview
15.4.2 Product portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Miltenyi Biotec GmbH
15.5.1 Company Overview
15.5.2 Product portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Qiagen N.V.
15.6.1 Company Overview
15.6.2 Product portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Thermo Fisher Scientific Inc.
15.7.1 Company Overview
15.7.2 Product portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 JSR Corporation (MBL International)
15.8.1 Company Overview
15.8.2 Product portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Illumina, Inc.
15.9.1 Company Overview
15.9.2 Product portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Takara Bio Inc.
15.10.1 Company Overview
15.10.2 Product portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Malvern Instruments Ltd. (Spectris Plc Company)
15.11.1 Company Overview
15.11.2 Product portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 Abcam Plc.
15.12.1 Company Overview
15.12.2 Product portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
15.13 Ampersand Capital Partner (New England Peptide, Inc.)
15.13.1 Company Overview
15.13.2 Product portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisitions
15.13.5 Certifications
15.14 Evox Therapeutics Ltd.
15.14.1 Company Overview
15.14.2 Product portfolio
15.14.3 Demographic Reach and Achievements
15.14.4 Mergers and Acquisitions
15.14.5 Certifications
16 Pricing Models and Strategies (Additional Insight)
16.1 Cost Model
16.1.1 Manufacturing Cost Analysis
16.1.2 Procurement Cost Analysis
16.2 Pricing Strategies
16.2.1 Competitor Pricing Analysis
16.2.2 Key Assessment of Product Attributes
16.2.3 Pricing Benchmark
17 Global Exosomes Drug Market- Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
*Additional insights provided are customisable as per client requirements.
The rising prevalence of cancer cases is driving the demand for exosome drugs. The prevalence of cancer cases is likely to grow at the rate of 6.6% during the forecast period of 2024-2032.
The rise in demand for drug therapy in the pharmaceutical and biopharmaceutical field is fuelled by the potential of exosome technology as a diagnostic and therapeutic tool used in the treatment of various diseases, such as neurodegeneration, cardiovascular dysfunction, and cancer.
Based on the product type, the market can be segmented into kits, reagents, and instruments.
Based on the application, the market can be segmented into biomarkers, drug delivery system, vaccine development, therapeutic agents, and others.
Based on the disease type, the market can be fragmented into cancer disease, neurodegenerative disease, cardiovascular disease, infectious disease, tissue regeneration, and others.
The major regions in the industry are North America, Latin America, the Middle East, Africa, Europe, and the Asia Pacific, with North America accounting for the largest share of the market .
North America is expected to dominate the market due to excellent healthcare infrastructure, effective government policies, large base of multinational corporations, and high public awareness about diagnosis and medical assistance.
Danaher Corporation (Beckman Coulter Inc.), Hologic Inc., Lonza Group AG, Fujifilm Holdings Corporation, Miltenyi Biotec GmbH, Qiagen N.V., Thermo Fisher Scientific Inc., JSR Corporation (MBL International), Illumina, Inc., Takara Bio Inc., Malvern Instruments Ltd. (Spectris Plc Company), Abcam Plc., Ampersand Capital Partner (New England Peptide, Inc.), and Evox Therapeutics Ltd. are the top companies in the exosome drug market.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.